Results 41 to 50 of about 42,053 (258)

Inhibitory effects of sulfenimides on human and bovine carbonic anhydrase enzymes

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2023
A series of sulfenimide derivatives (1a-i) were investigated as inhibitors of human (hCA-I, hCA-II) and bovine (bCA) carbonic anhydrase enzymes. The compounds were synthesised by the reaction of substituted thiophenols with phthalimide by means of an ...
Hasan Yakan   +12 more
doaj   +1 more source

Insights into the role of reactive sulfhydryl groups of Carbonic Anhydrase III and VII during oxidative damage [PDF]

open access: yes, 2016
Carbonic anhydrases (CAs) III and VII are two cytosolic isoforms of the α-CA family which catalyze the physiological reaction of carbon dioxide hydration to bicarbonate and proton.
De Simone, Giuseppina   +5 more
core   +1 more source

Purification of a fragment obtained by autolysis of a PIIIb-SVMP from Bothrops alternatus venom [PDF]

open access: yes, 2018
Snake Venom Metalloproteinases (SVMPs) represent 43.1% of the components in Bothrops alternatus venom and play an important role in envenomation. Disintegrins and disintegrin-like domains are released by proteolytic processing of PII and PIII classes of ...
Acosta, Ofelia Cristina   +9 more
core   +1 more source

Bottom‐Up Coacervate‐Based Artificial Cells: Integrating Cellular Hallmarks into Complex Life‐Like Systems

open access: yesAngewandte Chemie, EarlyView.
Current interest in artificial cell research underscores its potential to deepen our understanding of life's fundamental processes. This review highlights advances in bottom‐up coacervate‐based artificial cell engineering via combined integration of cellular hallmarks.
Arjan Hazegh Nikroo   +3 more
wiley   +2 more sources

Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms [PDF]

open access: yes, 2016
A large number of novel secondary sulfonamides based on the open saccharin scaffold were synthesized and evaluated as selective inhibitors of four different isoforms of human carbonic anhydrase (hCA I, II, IX and XII, EC 4.2.1.1).
Akdemir, Atilla   +9 more
core   +5 more sources

Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors. [PDF]

open access: yes, 2016
The inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) by chemical inhibitors, such as rapamycin, has demonstrated anti-cancer activity in preclinical and clinical trials.
Datta, D.   +11 more
core   +1 more source

Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis: Carbonic Anhydrase Inhibitors as Antithrombotics

open access: yesPlatelets, 2020
Carbonic anhydrase (CA) inhibitors have a long history of safe clinical use as mild diuretics, in the treatment of glaucoma and for altitude sickness prevention.
Ejaife O. Agbani   +6 more
doaj   +1 more source

Click chemistry approaches for developing carbonic anhydrase inhibitors and their applications

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2023
Click chemistry reactions constitute an important and relatively new approach in the medicinal chemistry toolbox and offer substantial advantages to medicinal chemists in terms of overcoming the limitations of facile chemical synthesis, increased ...
Andrea Angeli, Claudiu T. Supuran
doaj   +1 more source

Carbonic anhydrase inhibitory properties of some uracil derivatives

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2017
Inhibitors of carbonic anhydrase (CA) have been carried out in many therapeutic applications, especially antiglaucoma activity. In this study, we investigated some uracil derivatives (4–12) to inhibit human CA I (hCA I) and II (hCA II) isoenzymes. The KI
Emir Alper Türkoğlu   +3 more
doaj   +1 more source

Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models [PDF]

open access: yes, 2016
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality in the United States. Aggressive treatment regimens have not changed the disease course, and the median survival has just recently reached a year.
Carta, Fabrizio   +14 more
core   +2 more sources

Home - About - Disclaimer - Privacy